Isomorphic Labs drug enters human trials
- Isomorphic Labs said its first artificial-intelligence-designed drug candidates are now in human trials, with president Max Jaderberg disclosing the step at WIRED Health. - The company did not name the molecule or trial date, but said its pipeline spans multiple diseases and follows a $600 million funding round. - The move extends Isomorphic’s push from prediction tools into drug development partnerships with Lilly, Novartis and Johnson & Johnson. (isomorphiclabs.com)
Drug discovery starts with picking a protein target and finding a molecule that sticks to it in the right way. Isomorphic Labs says some of the molecules designed with its artificial intelligence systems have now entered human trials. (wired.com) Max Jaderberg, Isomorphic Labs’ president, said at WIRED Health in London on April 16 that the company was “going into clinical trials.” WIRED reported the company is now testing AI-designed drugs in people. (wired.com) Isomorphic Labs is a London-based Google DeepMind spinout led by Demis Hassabis. The company was created to turn protein-prediction advances such as AlphaFold into actual medicines. (isomorphiclabs.com 1) (isomorphiclabs.com 2) AlphaFold predicts the 3D shape of proteins, which are the tiny machines inside cells. Isomorphic says its newer Isomorphic Labs Drug Design Engine goes further by modeling how drug-like molecules bind, how strongly they bind, and where new binding pockets may exist. (isomorphiclabs.com) The company’s February 10, 2026 technical update said its system more than doubled AlphaFold 3’s accuracy on a protein-ligand benchmark. It also said the model beat physics-based methods on small-molecule binding-affinity prediction while using less time and cost. (isomorphiclabs.com) Human trials are the point where software predictions have to survive biology in real patients or volunteers. Early studies usually test safety, dosing, and how a drug behaves in the body before larger efficacy trials begin. (wired.com) Isomorphic has not publicly identified the specific drug candidate, disease target, trial registry number, or dosing details in the materials surfaced here. That leaves the public milestone clear, but the underlying clinical evidence still mostly undisclosed. (wired.com) (isomorphiclabs.com) The company has spent the past two years building commercial ties with large drugmakers while moving its own programs toward the clinic. In January 2024 it announced collaborations with Eli Lilly and Novartis worth nearly $3 billion in potential milestone payments and royalties, then expanded the Novartis deal in February 2025. (isomorphiclabs.com 1) (isomorphiclabs.com 2) Isomorphic added a Johnson & Johnson research collaboration on January 20, 2026, covering small molecules, antibodies, peptides, and molecular glues. That deal broadened the company beyond classic pill-like compounds into several drug formats. (isomorphiclabs.com) Investors also put fresh cash behind that plan. Isomorphic announced a $600 million external funding round on March 31, 2025, led by Thrive Capital with participation from GV and Alphabet. (isomorphiclabs.com) The next proof point is no longer whether Isomorphic can predict molecular structures on a computer. It is whether any of those designed molecules can clear the slow, regulated steps of human testing. (wired.com)
